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ABSTRACT 
The phenotypic changes in target cell induced by an exogenous agent, e.g. biologically 
active chemical, can be detected by labelling selected organelles with fluorescent dyes and 
observed under the high-throughput microscope. The changes of known biological targets (e.g. 
nucleus, proteins, mitochondria, microtubules, etc.) induced by a compound of interest allow 
predicting its mechanisms of action. High-throughput microscopy with capability of 
multiparametric imaging in combination with automated image-analysis is referred to as high-
content analysis or high-content screening (HCS). Recently, HCS plays an increasingly 
important role for a large-scale screening of small molecules for several aspects including anti-
cancer, anti-inflammatory activities, disease-related biomarkers and in vitro toxicity testing, and 
so on. As an introduction, this short review covers the concepts of HCS and its application in 
screening of biologically active natural products whose molecular targets could be identified 
through such approaches. 
Keywords: cell-based assay, high-content screening, automated microscope, imaging 
technology, bioactive natural-products. 
1. INTRODUCTION 
Natural products have largely been considered as an extraordinary valuable platform for the 
discovery of new drugs against diverse pathologies and a tool for the characterization of novel 
therapeutic targets as well. Despite recent advances in chromatographic and spectroscopic 
techniques and the rich tradition of the use of herbal medicines, still little effort of natural 
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product chemists has been directed towards isolating the bioactive chemical constituents from 
the natural sources. Reasons for this fact are related to the lack of expertise and infrastructure for 
biological screening, high costs as well as time consuming if samples must be sent to overseas 
laboratories. It is therefore highly desirable to develop in-house bioassays in institutes for 
chemical research which are inexpensive, rapid and do not require the chemists a specialized 
knowledge of biology or pharmacology [1-3]. The bioassay laboratories at Vietnam Academy of 
Science and Technology (VAST) had therefore initially established the “bench-top” bioassays 
since the 1990s. In recent years, some VAST’s laboratories have been further provided with 
essential and modern devices enabling development of more up-to-date methods to reduce 
subjective interpretation. Accordingly, this overview looks at the current screening method 
utilizing a modern technique, a high content screening (HCS), which is designed for various 
applications, not only in life science research but also in drug discovery to screen for hit 
compounds that impact cellular functions such as arrested cell-cycle, apoptosis, translocation, etc.  
2. GENERAL CONCERPT OF HCS 
The phenotypic changes in target cell induced by a bioactive compound can be detected by 
labelling selected organelles with fluorescent dyes and observed under the high-throughput 
microscope. A comparison of the cellular phenotype induced by a compound of interest with the 
phenotypes of reference compounds with known cellular targets allows predicting its mode of 
action [4, 5].  
  
Figure 1. A high content screening station (Olympus scan^R)  
at Institute of Natural Products Chemistry (INPC-VAST).  
HCS is a relatively new approach applied to detect changes at a cell and/or subcellular level 
with simultaneous readout of several parameters by using a high-throughput microscopy in 
combination with automated multiparametric-image analysis. Multiwavelength fluorescence 
imaging is the key technology for HCS platforms. This technology enables the detection of 
many cellular features in a single preparation, and imaging software can extract both qualitative 
and quantitative data from a variety of fluorescent parameters, e.g., fluorescence intensity, 
cellular and subcellular morphometrics, and a total count of features. Such HCS platforms 
acquire wavelength channels either sequentially or in parallel. With sequential acquisition, each 
fluorophore is separately excited and detected on a single monochrome charged coupled digital 
(CCD) camera. Most HCS systems are nowadays equipped with filter sets for the most common 
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fluorescent probes and can distinguish up to four or eight labels in a single preparation with 
minimal crosstalk between channels. Fluorescent microscopy imaging assays are therefore 
referred to as “high content” in comparison to most other cell-based assays that only generate 
single-parameter readouts [6-8]. 
In fact, HCS can be applied in two contexts. In a HCS experimental and data evaluation are 
more multiplex, thus going along with a lower throughput (smaller number) of tested 
compounds. The visual assessment of phenotypical changes of cells can add a significant 
measure to target- or mode of action predictions of uncharacterized compounds. Inversely, HCS 
can also be used as other high-throughput screening (HTS) methods since it has functioned well 
for rapidly and effectively screening large compound libraries of up to thousands of small 
molecules per day. In this context, a fixed endpoint and smaller number of parameters are often 
selected to facilitate automation (robotization), reduce procedural steps and data storage [4, 9]. 
Moreover, miniaturizing the imaging readout to a 96-, 384- or 1536-well format is advisable, 
thus a small volume of cells could be established. Nowadays a number of HCS platforms have 
been developed with a variety of design concepts based on the instruments versatility and overall 
cost, such as IN CELL Analyzer systems (GE Healthcare, Piscataway, NJ), Opera systems 
(Perkin Elmer, Waltham, MA), ImageXpress
®
 Micro/Ultra (Molecular Devices, Sunnyvale, 
CA), scan^R (Olympus Europa SE & Co.KG, Hamburg, DE), CellInsight™ CX (Thermo Fisher 
Scientific, Waltham, MA), etc. The growing availability of HCS infrastructure within research 
institutions has increasingly spurred interest in HCS applications among academic investigators.  
3. ESSENTIALS AND PERSPECTIVES OF HCS  
In general, HCS has been developed to meet the needs for flexible applications in both life 
science research and drug discovery. Screening steps in early drug discovery traditionally used 
primarily homogeneous assays because they were relatively simple “mix and read” assays. This 
approach was compatible with the prevailing view in the 1990s that stressed fast measurements 
on a growing list of targets with large numbers of compounds. Despite changing strategies in 
natural product research, in fact, the productivity of the whole pharmaceutical industry has 
decreased over the last decades leading to the exploitation of modern high-throughput 
technology to make changes in hit-to-lead stage. An alternative approach to easing key 
bottlenecks in the drug discovery process was suggested, based on HCS [11]. This image-based 
assay has opened the opportunity to perform drug discovery, not just on a preselected target, but 
to screen for compounds that impact cellular functions such as cell cycle, translocation, 
apoptosis, and so on [12]. A major bottleneck in the exploration of natural products as tools for 
chemical biology research and as lead structures for therapeutic applications is the identification 
of their mode of action on a molecular and cellular level. HCS method could be utilized to 
quickly identify a compound’s cellular target if this belongs to a known mode of action class. 
The compound can then be directed to specific target-based biochemical and/or biophysical 
assays to verify the hypothesis generated by HCA [4]. For compound profiles that cannot be 
matched, direct identification techniques, e.g. genetic screens or pulldown probes, could be 
further applied. Such a systematic approach may render the assignment of a biological profile for 
natural products more efficient and increase their value for life sciences significantly. 
In recent years, technological developments in various fields such as HCS analysis 
software, in vitro cellular models, genome engineering, chemoinformatic tools and phenotypic 
compound libraries provided the investigators significant capabilities to measure various 
biological out- puts in the most physiopathologically relevant in vitro models. According to 
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Dorval et al. [10], however, to fully benefit from the of HCS’s capabilities for either target or 
drug discovery, it is critical to select the appropriate projects, taking into account (i) the level of 
understanding of the molecular processes involved in the biology of interest, (ii) the availability 
of a physiopathologically relevant in vitro models adapted to medium and large scale screening 
campaigns, (iii) the ability to select and measure the most appropriate and diversified phenotypic 
and functional features to provide a sufficient level of agnosticism and finally, (iv) the selection 
of multiple and appropriate controls to fully enable HCS capabilities and adequate hit selection. 
Furthermore, the current artificial intelligence (AI) revolution will catalyze further major 
evolutions in the way HCS is used. These powerful tools are rapidly synergizing with HCS 
capabilities to bring image-based chemical compound screening into a new dimension. Indeed, 
the intrinsic data rich characteristics of HCS allows the extraction of a set of features, which 
include not just shape and spatial metrics but also the intensity and patterning of fluorescently 
labeled markers, and therefore could be used to define image-based compound fingerprints. 
Recently, it was demonstrated that image-based compound fingerprints acquired in the context 
of one HCS campaign could be repurposed to predict compound activity in different customized 
biological assays and, therefore, dramatically reduce the scale of screens implemented for other 
projects. 
4. ADVANTAGES OF HCS IN COMPARISON TO CURRENT ASSAY METHODS 
Cell viability, signaling and transcription as well as disease-related characteristics are the 
main phenotypic readouts commonly performed in screening of hit compounds. Thus, cell 
proliferation and/or cell death have been the predominant phenotypic readout using e.g. Alamar  
Blue assay, the colorimetric SRB, MTT assays or the ATP content assay [13]. Although these 
types of readout are productive and informative, they clearly provide only a single information 
readout per well. Intracellular signaling and transcription assays generally provide a simple link 
between a complex network of protein interactions and a specific transcription event of interest 
through pathway driven or active promoter reporter genes such as luciferase and β-lactamase, 
fluorescent proteins (GFP, YFP), which produces an easily measurable luminescence or 
fluorescence signal [14]. Although, many single readout assays were used to detect the changes 
of disease-specific cellular and/or functional phenotypes such as morphological changes, 
invasion, migration, differentiation or epithelial-to-mesenchymal transition, HCS approaches 
have obviously become the approach of choice. This trend is exemplified by the ability of HCS 
to combines automated fluorescence microscopy with quantitative image analysis, allowing the 
acquisition of unbiased multi-parametric data at the single cell level. HCS has the potential to 
combine cell viability, cell signaling and transcription, and/or phenotypic readouts in a single 
well across a large number of conditions in a target-based, phenotypic or combined target-
phenotypic drug discovery mode. Therefore, in a single assay, HCS technology has the potential 
to predict and integrate key biological activities of compounds during the early stages of the 
drug discovery process [10, 15].  
Enzyme-linked immunosorbent assay (ELISA) is designed to capture and quantify the 
amount of specific proteins or peptides by their epitopes using high affinity antibodies. 
Typically, the target proteins are either already purified or come from an extract of cells, 
resulting in the loss of spatial context. Therefore, it is impossible to readily identify which cells 
had a protein and where it was inside them. Many HCS assays also use antibodies as 
immunocytochemical affinity tags to label various cellular proteins, but retain the advantage of 
individual cell measures and subcellular location. Gasparri et al. [16] developed a HCS assay for 
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proliferation of human dermal fibroblasts with fluorescent indicators for brdU incorporation, 
histone H3 phosphorylation, pRb phosphorylation, and KI-67 expression. Cross-validation by 
ELISA and flow cytometry uncovered comparatively fewer false-positive/-negative rates with 
the HCS assay, leading to the assertion that HCS data were inherently of higher quality. In 
summary, the authors cited higher accuracy of data, both single-cell and population readouts, 
and the ability to report morphological features as important advantages of the HCS approach. 
Vogt et al. [17] performed a HCS for screening of inhibition activity of ERK dephosphorylation 
and confirmed the hits by visually inspecting cell images and with standard Western blotting 
techniques. Analysis of the data showed that this group of compounds was enriched for known 
cdc25 inhibitors. In vitro enzyme assays showed that the ERK inhibitors identified in the HCS 
inhibited at least one of the DSPases (MKP-3, cdc25B, cdc25A). The authors then performed a 
multi-parameter high content assay for MKP-3 and ERK phosphorylation in the two 
subpopulations. They reported a significant measurable difference in phospho-ERK 
accumulation between the MPK-3 overexpressing cells and the untransfected cells in the same 
wells. Additionally, the group determined that the compound having the best cellular activity 
was not one identified as potent in the biochemical screen, suggesting that performing this type 
of cell-based assay earlier in the drug discovery process is useful. 
Flow cytometry or automated cell sorting has likely the most critical advantage when 
approaching a cell-based assay for the last three decades. However, cell sorting in general does 
not lend itself to adherent cell lines and there are a very limited number of morphologies that can 
be measured. Structure-related measurements on a cell are difficult to make due to the flow of 
the sample. The process is to flow a stream of single cells, passing them through a laser beam to 
be detected, so it requires the use of large sample volumes and results in high quantities of 
potentially hazardous wastes. Other considerations for flow cytometry include its high cost, 
large size, and high maintenance. The greatest advantage of image-based platform HCS is the 
ability to see and record the biology by means of a picture. Table 1 shows a variety of cell-based 
methods and how these map to features that are often significant when looking to implementing 
a cell-based assay [7, 18]. Besides possessing the capability to analyze processes like protein 
phosphorylation, receptor/ligand interactions, protein expression, cell cycle regulation, enzyme 
activation or cell proliferation, HCA excels at discerning cell-morphological changes from 
images of thousands of individual cells, which are generally not traceable by conventional 
biochemical methods. Morphological changes include intracellular protein translocation, 
organelle structure changes e.g. in mitochondrial membrane potential, cytoskeletal remodeling, 
formation of micronuclei or quantification of internalization. This approach then allows for 
profiling of dose-dependent phenotypic effects induced by different compounds targeting 
distinct cellular processes. Generally, simultaneous acquisition of data on different properties of 
cells and their components to allow a more thorough understanding of sample effects is the main 
advantage of HCS method over other high-throughput methods. An additional advantage of HCS 
is its flexibility in assay development, e.g. gene expression, protein localization, RNAi 
screening, G-protein-coupled receptor (GPCR) activation, general signal-transduction and 
induced pluripotent stem cells (iPSC)-based assays. 
Although HCS represents a very attractive approach as described above, designing, 
performing and interpreting HCS assays is comparatively complicated. Several key elements 
therefore should be carefully considered. Thus, by multiplexing the readouts extracted from a 
biological assay, the high-content approach allows the monitoring of not only compound 
efficacy, but also potential toxicity, screening artifacts, as well as various mechanisms of action 
associated to treatment. This list of descriptors is usually called phenotypic signature or 
fingerprint and represents the keystone of HCS but also its weakness, as it could lead to “highly 
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precise” false positives. A set of principles has been established to facilitate the definition and 
development of disease-relevant assays, taking advantage of the latest advances in cell-based 
assay technologies [10, 19]. To select the model of interest, an understanding of the biology at 
the molecular level, including the cause of the disease of interest, is required. Moreover, many 
parameters are interdependent, e.g. the cell type determines transfection protocol and 
experimental timescale. An imaging assay also comprises cell fixation, staining, and 
microscopy, which must be adapted for the screen. Consequently, Boutros et al. [20] suggested 
that image-analysis steps should be implemented in parallel because this procedure provides 
direct feedback on the suitability of the assay.  
Table 1. Capabilities of variety of cell-based methods [18]. 
 
4. APPLICATION EXAMPLES OF HCS IN NATURAL PRODUCT RESEARCH 
The HCS platform was based on many years of basic biomedical research, including the 
development of research imaging microscopy, imaging technology, and reagents. The two 
earliest publications on the application of HCS to drug discovery were studies on the 
translocation of NF-κB, a key role in inflammatory diseases, induced by interleukin-1 and tumor 
necrosis factor (TNF-α) and on the internalization of a GFP-tagged G-protein-coupled receptor 
[21, 22]. In a study by Young et al. [23] HCS was performed to array cells treated with a total of 
6,547 different compounds, 58 % of which were of natural origin.  A total of 36 cytological 
features were extracted and reduced to 6 significant factors. For instance, 12 of the original 
features were combined to a single factor nuclear size. Eventually, the top 5 % of the whole 
screening set of 211 compounds whose induced phenotypic responses were significantly 
different to the average control phenotypes were identified as hits. 96 % of all hit compounds 
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with similar structure showed similar phenotypes, such as the aurantimycin A and diperamycin 
or the glucocorticoids clobetasol-17-propionate and dexamethasone.  
One of the most important applications of HCS is in searching for hit compounds with in 
vitro anticancer activity. For this bioactivity, several main subcellular molecules of cancer cells 
have been usually targeted like cell-cycle arrest, expression of apoptosis-regulating proteins and 
enzymes (e.g. Bcl-2 family, caspases), phosphoinositide 3-kinase (PI3K) and PI3K/Akt 
signalling pathway, mitochondria, and microtubule (tubulin), etc. For instance, Caie et al. [24] 
correlated phenotypic drug response with several cancer cell types of different genetic 
background. HCS was run in a four-wavelength assay with four different cancer cell lines. After 
segmentation of imaged cells by identifying nuclear and cytoplasmic boundaries, 100 features 
were extracted. It was found that some compounds, e.g. the microtubule stabilizer epothilone B, 
induced similar phenotypes across all cell lines tested. In case of the translation inhibitor 
emetine, phenotypic responses of the cell lines cluster differently, indicating highly sensitive, 
cell-specific responses against this particular drug. It was assumed that p53 is important for 
emetine activity, as the phenotypic profile of MCF7-p53 (an MCF7 derivative that expresses 
p53)  was significantly different to drug-sensitive wild-type parent line MCF7-wt. Wei et al. 
[25] investigated effects of Jaspolide B, a novel isomalabaricane-type triterpene isolated from 
sponge Jaspis sp., on human hepatoma cells by HCS assays. In this study, incubation with 0.5 
µM of jaspolide B caused time-dependent induction of apoptosis in up to 66.8 % of Bel-7402 
cells for 48 h, which was confirmed by the enhancement of mitochondrial masses and cell 
membrane permeability, and nuclear condensation in Bel-7402 and HepG2 cells. Moreover, 
jaspolide B arrested cell cycle progression at G1 phase of human hepatoma cells in a dose- and 
time-dependent manner. In addition, treatment of the compound caused dose-dependent 
disassembly of microtubule cytoskeleton in Bel-7402 cells at indicated concentrations, and this 
effect being similar but weaker than that of colchicine, a well-known microtubule-disassembly 
agent. In another study, 1,000 compounds including many natural products were screened by 
Perlman et al. [26] and a sum of 93 descriptors was extracted from stained cells. For generating 
compound profiles, the descriptors were plotted as a cumulative distribution and then reduced to 
a single number that represented the point of maximum difference between the control and 
treated population. For 61 of the 100 compounds, a strong response was obtained by this 
analysis. Structurally unrelated compounds sharing a common target showed similar response 
profiles. For the subset of kinase inhibitors no clustering was observed even in case of 
overlapping targets, maybe due to a variable inhibition of other kinases. The authors also 
included three poorly characterized compounds in their profiling approach. One of these, 
austocystin, clustered together with transcription and translation inhibitors. In this case, HCA 
correctly assigned a compound to a mode of action class. Austocystin D was later on shown to 
be activated by CYP-enzymes and to induce DNA damage [27]. Link et al. [28] reported the 
first potent and selective phosphoinositide 3-kinase (PI3K) inhibitor that has been discovered 
and developed using HCS. Activation of the phosphoinositide 3-kinase (PI3K)/Akt signalling 
pathway is one the most frequent genetic events in human cancer. A HCS assay that monitored 
the translocation of the Akt effector protein (FOXO) was employed to screen a collection of 
33,992 compounds. Pyrazolopyrimidine derivatives were found to be potent FOXO relocators as 
well as biochemical inhibitors of PI3Kalpha. A combination of virtual screening and molecular 
modelling led to the development of a structure-activity relationship for synthesis of ETP-45658, 
which is a selective PI3K-inhibitor and demonstrates mechanism of action in tumor cell lines 
and in vivo in treated mice.  
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Interestingly, the publications in 2016 from the Quinn group, AU demonstrating how to 
couple phenotypic screening against non-immortalized human olfactory neurosphere-derived 
(hONS) cells (primary cells derived from Parkinson’s disease patients) with pure natural 
products using a HCS system. The first screen covered isolated metabolites from marine sponges 
(Jaspis splendens) to prove that the overall system could function. The following screen then 
utilized a 500-plus pure compound set from the Nature Bank collection at Griffith University [1, 
4, 29, 30]. The results demonstrated that such a HCS produced multiple possibilities for the 
identification of the interaction(s) with cellular organelles/protein interactions, being limited 
only by the specificity of the fluorescent probes used to demonstrate the responses. To further 
demonstrate the potential of such HCS, recently an excellent review covering progression in 
techniques and technologies from 1997 to the end of 2015 as well as almost all aspects of HCS 
was published by a research group from the Helmholtz Centre in Braunschweig, DE. In addition, 
iPSC-based assay can be used in large-scale primary screening to finding drug candidates with 
regards to molecular targets and/or mechanisms of action. For instance, Sherman & Bang [31] 
demonstrated the feasibility of high-throughput screening of human iPSC-derived neurons using 
an image-based high-content approach to screen a collection of 4,421 bioactive compounds. The 
novel findings are three natural products: 2-methoxy-phenylacryloyl-lupinine, which promoted 
neurite outgrowth, and two Chinese herbal medicines, the diterpenes, andrographolide and 
triptolide, which inhibited neurites. Another hit not previously implicated in neuritogenesis was 
the smooth muscle relaxant alverine citrate, which promoted neurite outgrowth in this report. 
Moreover, three long-chain saturated fatty acids (FAs) were identified as novel neurite growth-
promoting hits. A number of compounds for which activity was opposite to previous reports, e.g. 
the sodium channel blocker dibucaine identified as neurite outgrowth promoting in this screen, 
but shown previously to inhibit neurites. 
Not least, the HCS could be considered as a key role in the detection of toxicity and 
classification of the compounds on the basis of cellular injury. Tolosa et al. [32] designed an in 
vitro testing approach that is capable of potential liver toxicity, which is a major reason for drug 
non-approvals and withdrawals. Accordingly, HepG2 human cell line was exposed to 78 
different natural- and synthetic chemicals at a range of concentrations (1-1,000 µM) and then 
analysed with the HCS station scan^R (Olympus). Thus, cell parameters associated with nuclear 
morphology, plasma membrane integrity, mitochondrial function, intracellular calcium 
concentration, and oxidative stress, indicative of pre-lethal cytotoxic effects and representative 
of different mechanisms of toxicity were measured at the single cells level, which allows high-
throughput screening. This strategy appears to identify early and late events in the hepatotoxic 
process and suggests the mechanism(s) implicated in the toxicity of compounds or drugs to 
thereby classify them according to their degree of injury. As the results, fluoxetine, imipramine, 
maprotiline, and rotenone may cause a high incidence of liver-cell injury at experimental 
concentration of 100 µM; whilst  hepatotoxicity of moderate injury were detected for e.g. 17 -
ethinylestradiol (a synthetic derivative of the natural steroid-hormone estradiol), aflatoxin B1, 
colchicine, cycloheximide, cyclosporine A, erythromycin, etoposide, simvastatin, and lovastatin. 
At INPC-VAST, we have been recently developed the fluorescent image-based HCS 
towards screening of the anti-cancer, anti-inflammatory activities as well as in vitro cytotoxic 
effects of compounds or drugs with regards to molecular targets, e.g. NF-κB translocation, cell-
cycle arrest, early and late-stage apoptosis, mitochondrial changes, and neurotoxicity using 
mouse hippocampal neuronal-cell model, etc. Acquisition and image analysis of living or fixed 
cells after treatment with natural- or synthetic chemicals are carried out with a HCS station 
 
 
Application of image-based high content analysis for the screening of bioactive natural-products  
 
9 
scan^R that allows the simultaneous quantification of selected biological targets stained by 
corresponding fluorescent dyes (Figure 2). 
       
   
Figure 2. The use of high-content screening station at INPC-VAST for arrested cell-cycle analysis (Hep-
G2 cell line; upper figure) and NF-κB p65 translocation in HeLa cells (lower figure). Cells (10,000 
cells/well of a 96-well plate) were stained with DAPI, GFP after treatment with 1-20 µM test compounds. 
Images were taken with 20x/40x objectives, sCMOS camera (Hamamatsu ORCA-flash 4.0, JP) and 
analyzed by using a scan^R Analysis ver.2.7.2 software. 
5. CONCLUSION 
A major bottleneck in the screening of natural products as tools for hit identification in 
chemical biology research is the identification of their mode of action or targets on individual 
cell and subcellular level. High-content screening (HCS) has been recognized as an alternative 
approach to easing these key bottlenecks and plays an increasingly important role in both early 
and late-stage drug discovery for two decades. It is also expected that in vitro toxicology will be 
the next major area of HCS application in drug development process, which may ultimately 
predict in vivo toxicity and classification of compounds basing on their degree of cellular injury.  
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